Mosaic ImmunoEngineering (CPMV) Cash from Discontinued Operations (2011 - 2015)
Mosaic ImmunoEngineering (CPMV) posted quarterly Cash from Discontinued Operations of 3862.0 for Q2 2015, down 35.63% year-over-year from 6000.0 in Q2 2014, and up 728.76% quarter-over-quarter from 466.0 in Q1 2015.
Mosaic ImmunoEngineering (CPMV) Cash from Discontinued Operations (2011 - 2015) Analysis & Trends
Mosaic ImmunoEngineering's Cash from Discontinued Operations history runs 5 years deep, the most recent figure standing at 3862.0 for Q2 2015.
- In Q2 2015, Cash from Discontinued Operations fell 35.63% year-over-year to 3862.0; the TTM figure through Feb 2016 stood at 3862.0 (down 93.31% YoY), while the FY2015 annual figure was 55604.0, down 23.06% from the prior year.
- Cash from Discontinued Operations for Q2 2015 stood at 3862.0, up from 466.0 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 263475.0 in Q1 2012, with the low at 1519758.0 in Q2 2011.
- The 5-year median for Cash from Discontinued Operations is 5133.0 (2013), against an average of 101936.35.
- Peak annual rise in Cash from Discontinued Operations reached 695.97% in 2013, while the deepest fall reached 98.05% in 2013.
- Mosaic ImmunoEngineering's Cash from Discontinued Operations stood at 14586.0 in 2011, then tumbled by 57.49% to 6201.0 in 2012, then jumped by 695.97% to 49358.0 in 2013, then plunged by 94.33% to 2800.0 in 2014, then soared by 37.93% to 3862.0 in 2015.
- Business Quant data shows CPMV's Cash from Discontinued Operations at 3862.0 in Q2 2015, 466.0 in Q1 2015, and 2800.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2015 | 3,862.00 |
| May 31, 2015 | 3,862.00 |
| Feb 28, 2015 | 466.00 |
| Feb 28, 2015 | 466.00 |
| Nov 30, 2014 | 2,800.00 |
| Nov 30, 2014 | 2,800.00 |
| Aug 31, 2014 | 48,476.00 |
| Aug 31, 2014 | 48,476.00 |
| May 31, 2014 | 6,000.00 |
| May 31, 2014 | 6,000.00 |
| Feb 28, 2014 | 6,225.00 |
| Feb 28, 2014 | 6,225.00 |
| Nov 30, 2013 | 49,358.00 |
| Nov 30, 2013 | 49,358.00 |
| Aug 31, 2013 | 10,683.00 |
| Aug 31, 2013 | 10,683.00 |
| May 31, 2013 | 5,009.00 |
| May 31, 2013 | 5,009.00 |
| Feb 28, 2013 | 5,133.00 |
| Feb 28, 2013 | 5,133.00 |